Kolexia
Regnault Helene Gastro-entérologie
Regnault Helene
Gastro-entérologie
Hôpital Henri Mondor
Créteil, France
74 Activités
106 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinome hépatocellulaire Carcinomes Tumeurs du foie Cholangiocarcinome Tumeurs des canaux biliaires Hépatite Métastase tumorale Maladies du foie Hépatite C

Collaborateurs

Voir plus
Amaddeo Giuliana
Amaddeo Giuliana
Hôpital Henri Mondor, Créteil, France
Luciani Alain
Luciani Alain
Hôpital Henri Mondor, Créteil, France
Calderaro Julien
Calderaro Julien
Hôpital Henri Mondor, Créteil, France
Laurent Alexis
Laurent Alexis
Hôpital Henri Mondor, Créteil, France

Industries

Voir plus
Boston Scientific
6 collaboration(s)
Dernière en 2023
Ipsen
5 collaboration(s)
Dernière en 2023
Bayer
3 collaboration(s)
Dernière en 2023
Roche
2 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
PROACTIF: A Prospective, Post Approval, Multiple Centre, Open-Label, Non-Interventional, Registry Study to Evaluate Effectiveness of TheraSphere® in Clinical Practice in France
Essai Clinique (Boston Scientific)   21 février 2024
Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma.
Nature communications   14 décembre 2023
Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: A multicentric retrospective study.
United European gastroenterology journal   07 décembre 2023
TERTIO: Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: a Proof of Concept Randomized Phase II Study (TERTIO - Prodige 82)
Essai Clinique (CHU Besançon)   10 novembre 2023
SIRtain: Observational Study to Assess Real-World Outcomes in Patients With Unresectable Liver Tumors Initiating Treatment With SIR-Spheres (Y-90 Resin Microspheres) (SIRtain Registry)
Essai Clinique (Sirtex Medical)   31 juillet 2023
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).
BMC cancer   29 juillet 2023
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What's new 12 months later?
Annals of hepatology   17 juillet 2023
TACE and conformal radiotherapy . TACE alone for hepatocellular carcinoma: A randomised controlled trial.
JHEP reports : innovation in hepatology   29 janvier 2023
TRIPLET: Randomised, Open-label, Phase II-III Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy
Essai Clinique (Fédération Francophone de Cancérologie Digestive)   27 décembre 2022
Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma.
Journal of hepatology   18 août 2022